Cargando…
Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial
Autores principales: | Strefford, JC, Kadalayil, L, Forster, J, Rose-Zerilli, MJJ, Parker, A, Lin, TT, Heppel, N, Norris, K, Gardiner, A, Davies, Z, Gonzalez de Castro, D, Else, M, Steele, AJ, Parker, H, Stankovic, T, Pepper, C, Fegan, C, Baird, D, Collins, A, Catovsky, D, Oscier, DG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676082/ https://www.ncbi.nlm.nih.gov/pubmed/26256637 http://dx.doi.org/10.1038/leu.2015.217 |
Ejemplares similares
-
The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial
por: Oscier, David, et al.
Publicado: (2016) -
Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial
por: Larrayoz, M, et al.
Publicado: (2017) -
The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
por: Else, Monica, et al.
Publicado: (2015) -
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial
por: Blakemore, Stuart J., et al.
Publicado: (2020) -
The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial
por: Else, Monica, et al.
Publicado: (2021)